Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoLiMoR: Intermittent Cetuximab in RAS-mutant mCRC
NCT04554836Phase 2Completed
- Start
- Dec 2020
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC). Started Dec 2020; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04554836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554836.